XML 40 R28.htm IDEA: XBRL DOCUMENT

Note 22 - Fair Value Disclosures

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Fair Value Disclosures [Text Block]

NOTE 22 – FAIR VALUE DISCLOSURES

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

The fair value of the Company’s financial instruments are as follows:

		Fair Value Measured at Reporting Date Using
		Carrying Amount				Level 1				Level 2				Level 3				Fair Value
At December 31, 2021:
Cash and cash equivalents		$	193,198			$	-			$	193,198			$	-			$	193,198
Note receivable – CEN Biotech Ukraine, LLC – related party		$	44,859			$	-			$	-			$	44,859			$	44,859
Advances to CEN Biotech Ukraine, LLC - related party		$	1,299,328			$	-			$	-			$	1,299,328			$	1,299,328
Loans payable		$	1,688,793			$	-			$	-			$	1,688,793			$	1,688,793
Loans payable – related parties		$	2,701,641			$	-			$	-			$	-			$	-
Convertible notes payable		$	643,330			$	-			$	-			$	1,890,736			$	1,890,736
Convertible notes payable – related parties		$	162,639			$	-			$	-			$	-			$	-
CEBA loan payable		$	31,552			$	-			$	-			$	31,552			$	31,552

		Carrying Amount				Level 1				Level 2				Level 3				Fair Value
At December 31, 2020:
Cash and cash equivalents		$	1,908			$	-			$	1,908			$	-			$	1,908
Other receivables		$	113,999			$	-			$	-			$	113,999			$	113,999
Note receivable – CEN Biotech Ukraine, LLC – related party		$	44,859			$	-			$	-			$	44,859			$	44,859
Advances to Emergence Global - related party		$	17,901			$	-			$	-			$	17,901			$	17,901
Advances to CEN Biotech Ukraine, LLC - related party		$	1,179,328			$	-			$	-			$	1,179,328			$	1,179,328
Loans payable		$	527,379			$	-			$	-			$	527,379			$	527,379
Loans payable – related parties		$	1,363,354			$	-			$	-			$	-			$	-
Patent acquisition liability		$	1,380,000			$	-			$	-			$	1,380,000			$	1,380,000
Convertible notes payable		$	6,730,448			$	-			$	-			$	7,766,663			$	7,766,663
Convertible notes payable – related parties		$	2,558,681			$	-			$	-			$	-			$	-

The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments.

The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.

The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.

It is not practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.

The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3^rd party valuation specialist prior to April 5, 2021. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies. Beginning April 5, 2021, the fair value of the patent acquisition liability was based upon the OTC closing price and accordingly was transferred from Level 3 to Level 1 due to the availability of published prices for CEN’s common stock during 2021. Effective October 7, 2021, the liability was settled with delivery of the associated common shares, see Note 8.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details